Spero Therapeutics is trading 9.2% up at $1.30 in pre-market, rebounding from recent weakness in a move that appears to be a light-volume technical bounce.
- There are no fresh company-specific headlines, earnings reports, FDA decisions, or analyst calls linked to the stock this morning.
- The upward move aligns with generally firmer index futures rather than a reaction to new fundamental developments.